Safety of injectable semaglutide for type 2 diabetes
The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Semaglutide is the most recently approved injectable glucagon-like peptide-1 receptor agonist (GLP-1RA) for people with type 2 diabetes (T2DM). It is one of the three currently marketed GLP-1RAs that can be administered once weekly. AREAS COVERED: This review focusses on the safety of injectable semaglutide. Semaglutide has been assessed in the SUSTAIN phase 3 clinical trial programme, which included patients across the disease spectrum, i.e. treatment-naïve to those receiving insulin. The authors have looked at all published literature on safety considerations of once weekly GLP-1RA with particular reference to semaglutide. EXPERT OPINION: Semaglutide is the most powerful injectable GLP-1RA. The cardiovascular (CV) outcome trial (SUSTAIN 6) showed CV superiority and its adverse event profile is as expected for the GLP-1RA class with predominantly gastrointestinal side-effects. Concerns about the thyroid and pancreatic safety have not been substantiated. There is no indication of renal or liver harm for semaglutide. Data consistent with reno-protection and benefit in liver disease is presented. There is a modest signal for increased gall bladder adverse events. An increase in diabetic retinopathy (DR) events in the SUSTAIN 6 trial is the most concerning safety signal. Caution regarding DR is needed when initiating semaglutide and recommendations are suggested.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Safety study of injectable semaglutide for type 2 diabetes suggested that the thyroid and pancreatic safety had not been substantiated (43).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [43]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“REWIND CVOTs for two other powerful glucose-lowering GLP-1RAs (liraglutide and dulaglutide) [46,65].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“The FDA recommendations followed a meta-analysis which reported that a thiazolidinedione (rosiglitazone) increased the risk of MI in people with T2DM [35].”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · cited 1×
“of lipase and amylase were seen in human trials [49].”
Background
Research works printed but not linked: 6
- Centers for Disease Control and Prevention, 2011, National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States
- 2008, Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
- 2012, Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus
- 2012, LiverTox: clinical and research information on drug-induced liver injury [Internet]
- O’Neil PM, Lancet. 2018, 392, 637
- 2006, Drugs and lactation database (LactMed) [Internet]
Cited by
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
“Safety study of injectable semaglutide for type 2 diabetes suggested that the thyroid and pancreatic safety had not been substantiated (43).”
BackgroundWilliams, D. M., Ruslan, A. M., Khan, R., Vijayasingam, D., Iqbal, F., Shaikh, A., Lim, J., Chudleigh, R., Peter, R., Udiawar, M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01015-z · Cited by 31
Self-citationBerra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
“OW semaglutide is currently recognized as the most powerful molecule within the GLP-1RAs class (22).”
BackgroundThe current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
Spezani, R., & Mandarim-de-Lacerda, C. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120188 · Cited by 23
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
“Visbol et al subsequently conducted a detailed evaluation of DR data from the SUSTAIN clinical trial programme.(63) No difference in DR AEs was found comparing”
MethodSelf-citation
Metadata
- Authors
- Peter, R., & Bain, S. C.
- Affiliations
- Swansea Bay University Health Board (GB)
- Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2020-06-04
- Volume
- 19
- Issue
- 7
- Pages
- 785-798
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W3027159009
- Cited by
- 17
- References
- 76
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, GLP-1 receptor agonists, drug safety, SUSTAIN trials, cardiovascular outcomes, gastrointestinal adverse effects, renal protection, liver disease, diabetic retinopathy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of injectable semaglutide for type 2 diabetes. https://app.cochat.ai/papers/10.1080/14740338.2020.1772230
- The paper
- Peter, R., & Bain, S. C. (2020). Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2020.1772230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.